All In Biotech

Investigational drug · Phase 3

HL-1186

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN ).

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

7

Any phase or sponsor naming "HL-1186"

First trial start

2025

Aug 8, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HL-1186", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Postoperative Pain
  • Moderate to Severe Acute Postoperative Pain
  • Postherpetic Neuralgia ( PHN )
  • Diabetic Peripheral Neuropathic Pain

Approved drugs for the same conditions: Neuropathic pain · Cardiovascular and metabolic · Neurology · Pain and anesthesia

Largest trials

Live from ClinicalTrials.gov: studies naming "HL-1186" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Postoperative Pain

  • CPL-01local anaesthetic of CPL-01, Local anesthetic of CPL-01Phase 33 trials

    Cali Pharmaceuticals LLC · Bunion, Postoperative Pain, Hernia, Inguinal

  • SRP-001Phase 21 trial

    South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.